The New England Journal of Medicine on September 11 epublished the results of a trial of more than 4000 postmenopausal women with osteoporosis and a previous fragility fracture, in which a monoclonal antibody made by Thousand Oaks, CA-based Amgen outperformed a commonly used and effective osteoporosis medication in preventing new fractures. Investigators at the University of Alabama at Birmingham (UAB) randomly assigned the women to two groups
More here:
Amgen drug beats osteoporosis standard